(Nevada, Las Vegas) United States, DelveInsight’s “Buerger’s Disease – Pipeline Insight, 2023” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Buerger’s Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Buergers Disease Pipeline Report
-
Over 3+ companies and 3+ pipeline drugs in Alpha1-Antitrypsin Deficiency (AATD) pipeline landscape and their anticipated acceptance in the Burgers Disease market would significantly increase market revenue.
-
Leading Buergers Disease companies developing novel drug candidates to improve the Buergers Disease treatment landscape include Antidote Therapeutics, K-STEMCELL, Caladrius Biosciences, and others.
Phases
DelveInsight’s Report covers around 3+ products under different phases of clinical development like
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I) along with the details of
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
-
Route of Administration
Buerger’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Oral
-
Parenteral
-
Intravitreal
-
Subretinal
-
Topical
-
Molecule Type
Products have been categorized under various Molecule types such as
-
Monoclonal Antibody
-
Peptides
-
Polymer
-
Small molecule
-
Gene therapy
-
Product Type
Drugs have been categorized under various product types like Mono, Combination, and Mono/Combination.
-
Promising Buergers Disease pipeline therapies in various stages of development include Mesenchymal stem cell therapy, ATI-1013, and others
Buergers Disease Overview
Buerger’s disease also known as Thromboangiitis obliterans is a rare vascular disease in which blood vessels of the hands and feet become blocked. The affected individual may observe pain as early findings or coldness in the fingers. Later findings include fingers or toes that appear pale, red, or bluish; sudden severe pain in the hands and feet; skin ulcers; gangrene, and eventual amputation. A diagnosis to check blockage of blood vessels can be done through plethysmography, Doppler ultrasound of the extremity, or Catheter-based x-ray arteriogram. Blood tests for other causes of inflamed blood vessels (vasculitis) and blocked (occlusion of) blood vessels may be done. The goal of treatment for Buerger’s disease is to control symptoms and prevent the disease from getting worse.
Buergers Disease Pipeline Analysis: Drug Profile
Mesenchymal stem cell therapy: K-STEMCELL
Mesenchymal stem cell therapy is a drug candidate that improves or treats ischemic ulcers, etc. caused by Burger’s disease. VascoStem, once injected, indirectly vascularizes through the vascular endothelial cell growth factor (VEGF) secreted from VascoStem, and directly restores the damaged tissue. The molecule is in Phase I/II clinical trial for the treatment of Buerger’s Disease. VascoStem has been awarded a rare pharmaceutical product from the Food and Drug Administration (FDA) in May 2016 as a treatment for berger disease, based on the results of Phase I/II clinical trials in Korea. In addition, the European Medicines Agency (EMA) in March 2017, granted orphan drug designation.
Discover more about the emerging Buergers Disease drugs @ Buergers Disease Treatment Drugs
Buergers Disease Pipeline Therapies and Key Companies
Mesenchymal stem cell therapy: K-STEMCELL
ATI-1013: Antidote Therapeutics
And many others
Buergers Disease Pipeline Therapeutics Assessment
This segment of the report provides insights about the different Buerger’s Disease drugs segregated based on the following parameters that define the scope of the report, such as:
Major Players in Buerger’s Disease
There are approx. 3+ key companies which are developing therapies for Buerger’s Disease. The companies which have their Buerger’s Disease drug candidates in the most advanced stage, i.e. Phase III include Caladrius Biosciences.
DelveInsight’s Report covers around 3+ products under different phases of clinical development like
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I) along with the details of
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
-
Route of Administration
Buerger’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Oral
-
Parenteral
-
Intravitreal
-
Subretinal
-
Topical
-
Molecule Type
Products have been categorized under various Molecule types such as
-
Monoclonal Antibody
-
Peptides
-
Polymer
-
Small molecule
-
Gene therapy
-
Product Type
Drugs have been categorized under various product types like Mono, Combination, and Mono/Combination.
Scope of the Buergers Disease Pipeline Report
-
Coverage: Global
-
Key Alpha1 Antitrypsin Deficiency Companies: Antidote Therapeutics, K-STEMCELL, Caladrius Biosciences, and others
-
Key Buergers Disease Pipeline Therapies: ATI-1013, Mesenchymal stem cell therapy, and others.
-
Find out more about the Buergers Disease treatment options in development @ Buergers Disease Clinical Trials
Table of Contents
1. Buergers Disease Introduction
2. Buergers Disease Executive Summary
3. Buergers Disease Overview
4. Buergers Disease Pipeline Therapeutics
5. Buergers Disease Late-Stage Products (Phase III)
6. Buergers Disease Mid-Stage Products (Phase II)
7. Buergers Disease Early Stage Products (Phase I/II)
8. Buergers Disease Preclinical Stage Products
9. Buergers Disease Discovery Stage Products
10. Buergers Disease Therapeutic Assessment
11. Buergers Disease Inactive Products
12. Buergers Disease Collaborations Assessment- Licensing / Partnering / Funding
13. Buergers Disease Unmet Needs
14. Buergers Disease Market Drivers and Barriers
15. Appendix
16. About DelveInsight
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services